Evidence map›Paper›PMID 41373864›Full record

ArticleInternational journal of molecular sciences2025

MicroRNA-1 Suppresses Tumor Progression and UHRF1 Expression in Cholangiocarcinoma.

Makoto Muto, Teruhide Ishigame, Takashi Kimura, Naoya Sato, Yasuhide Kofunato, Akira Kenjo, Hiroyuki Yamamoto, Yuhki Yokoyama, Hirofumi Yamamoto, Shigeru Marubashi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Makoto MutoDepartment of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.ORCID 0009-0000-1817-6918
Teruhide IshigameDepartment of Gastrointestinal Surgery, Aizu Medical Center, Fukushima Medical University, 21-2 Maeda, Yazawa, Kawahigashi-machi, Aizuwakamatsu 969-3492, Japan.
Takashi KimuraDepartment of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.ORCID 0000-0003-2303-1320
Naoya SatoDepartment of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.ORCID 0000-0003-4572-7855
Yasuhide KofunatoDepartment of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Akira KenjoDepartment of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Hiroyuki YamamotoDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita 565-0871, Japan.
Yuhki YokoyamaDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita 565-0871, Japan.
Hirofumi YamamotoDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita 565-0871, Japan.ORCID 0000-0001-6959-9574
Shigeru MarubashiDepartment of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) have been shown to suppress tumor progression in several cancers, including cholangiocarcinoma; however, their mechanisms and roles remain largely unexplored. In this study, we aimed to identify novel miRNAs and molecules associated with cholangiocarcinoma progression. Using miRNA and mRNA microarrays from surgically resected specimens, we identified microRNA-1 (miR-1) as significantly downregulated in cholangiocarcinoma tissues and selected it for further analysis. In the in vitro assay, miR-1 was transfected into cholangiocarcinoma cell lines to assess its effect on tumor progression. Proliferation and migration/invasion assays demonstrated significant tumor suppression in miR-1-transfected cells. Additionally, cell cycle and apoptosis assays revealed an increase in cells in the G1 and G2/M phases, a decrease in the S phase, and an elevation in apoptosis rates in miR-1-transfected cells. Further analysis of the miRNA and mRNA microarray data identified ubiquitin-like with plant homeodomain and ring finger domains 1 (UHRF1) as a molecule potentially associated with miR-1. Quantitative RT-PCR and Western blotting analysis confirmed that UHRF1 expression was suppressed following miR-1 transfection. This study demonstrated that cholangiocarcinoma progression was suppressed by restoring miR-1 expression, suggesting that UHRF1 expression is involved in cholangiocarcinoma progression. The results of this study provide new insights into the molecular mechanisms underlying cholangiocarcinoma progression.

Indexed as

Bile Duct NeoplasmsCCAAT-Enhancer-Binding ProteinsCholangiocarcinomaGene Expression Regulation, NeoplasticMicroRNAsApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleHumansMaleMiddle AgedUbiquitin-Protein LigasesCCAAT-Enhancer-Binding ProteinsMicroRNAsMIRN1 microRNA, humanUbiquitin-Protein LigasesUHRF1 protein, humancholangiocarcinomamicroarraymicroRNAmiR-1UHRF1

Identifiers

PMID41373864
PMCPMC12692032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.